Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07161193 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases
Trial Details
NCT Number NCT07161193
Lead Sponsor Hebei Senlang Biotechnology Inc., Ltd.
Collaborators: The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, Luoyang, China
Conditions Autoimmune Diseases
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov